Hill-Rom Holdings, Inc. (NYSE:HRC) SVP Paul Sherwood Johnson sold 11,575 shares of the firm’s stock in a transaction dated Thursday, April 8th. The stock was sold at an average price of $111.04, for a total value of $1,285,288.00. Following the completion of the transaction, the senior vice president now directly owns 6,920 shares in the company, valued at $768,396.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
HRC stock opened at $113.90 on Thursday. Hill-Rom Holdings, Inc. has a twelve month low of $80.31 and a twelve month high of $117.68. The company has a quick ratio of 1.06, a current ratio of 1.43 and a debt-to-equity ratio of 0.96. The stock has a market cap of $7.56 billion, a P/E ratio of 34.31, a PEG ratio of 3.00 and a beta of 0.58. The business’s 50-day moving average price is $108.56 and its 200-day moving average price is $99.22.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Thursday, February 4th. The medical technology company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.48. Hill-Rom had a return on equity of 22.71% and a net margin of 7.74%. The firm had revenue of $741.10 million for the quarter, compared to analysts’ expectations of $654.41 million. During the same period in the previous year, the firm earned $1.13 EPS. The business’s quarterly revenue was up 8.2% on a year-over-year basis. On average, equities research analysts expect that Hill-Rom Holdings, Inc. will post 5.36 earnings per share for the current fiscal year.
HRC has been the topic of several research reports. Raymond James raised their target price on Hill-Rom from $113.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 16th. Robert W. Baird raised their target price on Hill-Rom from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, February 8th. Finally, Morgan Stanley raised their target price on Hill-Rom from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Monday, February 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $120.33.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Louisiana State Employees Retirement System raised its stake in Hill-Rom by 3.0% during the 1st quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the medical technology company’s stock valued at $1,900,000 after purchasing an additional 500 shares during the period. Mountain Pacific Investment Advisers Inc. ID raised its stake in Hill-Rom by 12.5% during the 1st quarter. Mountain Pacific Investment Advisers Inc. ID now owns 301,819 shares of the medical technology company’s stock valued at $33,345,000 after purchasing an additional 33,580 shares during the period. tru Independence LLC bought a new stake in Hill-Rom during the 4th quarter valued at approximately $255,000. Teachers Retirement System of The State of Kentucky raised its stake in Hill-Rom by 18.1% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 205,140 shares of the medical technology company’s stock valued at $20,098,000 after purchasing an additional 31,375 shares during the period. Finally, Eaton Vance Management raised its stake in Hill-Rom by 5.9% during the 4th quarter. Eaton Vance Management now owns 36,774 shares of the medical technology company’s stock valued at $3,603,000 after purchasing an additional 2,047 shares during the period. 83.75% of the stock is currently owned by institutional investors.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment.
Read More: Marijuana Stocks Investing Considerations
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.